Anatara Lifesciences Ltd (ANR.AX) Quarterly financial report

Anatara Lifesciences Ltd

Anatara Lifesciences Ltd (ANR.AX) Quarterly financial report

Brisbane, Australia, October 28, 2020 – (ABN Newswire) – Anatara Lifesciences (ASX: ANR) is pleased to publish its Schedule 4C for the quarter ending September 30, 2020. The Company’s cash and term deposits at the end of the quarter amounted to $ 1.59 million (June 30, 2020: $ 2.7 million). As at September 30, 2020, the Company had cash in the bank of $ 1.09 million and $ 0.5 million in term deposits.

Net cash outflows during the quarter were 74% higher than the previous quarter due to the launch of the GaRP clinical trial. Ongoing cash preservation initiatives resulted in quarterly reductions in personnel costs of 17% (-44% in the September 2019 quarter) and administrative and corporate costs of 5% (-40% in the September 2019 quarter. ).

The total amount of payments to related parties and their partners during the quarter was $ 85,000, which includes directors’ fees and superannuation.

Planned cash outflows for the December 2020 quarter are expected to decrease compared to the September 2020 quarter which contained significant upfront costs associated with the launch of the GaRP clinical trial. Anatara also expects to receive an R&D tax incentive refund during the December 2020 quarter of $ 612,967.

Anatara announced during the quarter: (1) the initiation of a challenge study in poultry with the newly developed bromelain formulation (ANR-pf); (2) investor presentation made at ASX Small and Mid-Cap Conference 2020.

CEO Steve Lydeamore commented, “Anatara is delighted to have successfully completed an internship to advance a clinical study of Anatara’s GaRP in Irritable Bowel Syndrome (IBS). Along with executing its human health development plans, the company has prioritized removing barriers to the authorization of Detach (R) through progress in challenge testing for newly developed formulations for piglets in the diet) and for poultry. The company anticipates renewed interest in the partnership with Detach (R) once the provocation trials are successfully completed. ”

To view the report, please visit:
https://abnnewswire.net/lnk/06GG0LR1

About Anatara Lifesciences Ltd:

Anatara Lifesciences (ASX: ANR) develops and markets innovative, evidence-based products for gastrointestinal health where there is a significant unmet need. Anatara is a life sciences company with expertise in the development of products for animal and human health. Anatara is focused on building a pipeline of human gastrointestinal health products. At the root of this product development program is our commitment to deliver real results for patients and strong added value for our shareholders. For more information, please visit www.anataralifesciences.com.

Contact:

Investor and media surveys

Steven lydeamore
Chief executive officer
Anatara Lifesciences Ltd
T: + 61-438-027-172
E: [email protected]

Sue MacLeman
Chair
Anatara Lifesciences Ltd
T: + 61-437-211-200
E: [email protected]

Source:
Anatara Lifesciences Ltd

Copyright (C) 2020 ABN Newswire. All rights reserved.


Source link

About Rachel Gooch

Check Also

Judge dismisses CU’s dismissal of allegations of sexual harassment and retaliation from former executive

Source: Shutterstock. A federal judge has dismissed a demand from the retained $ 4.3 billion …

Leave a Reply

Your email address will not be published. Required fields are marked *